CB-839/cabozantinib combination in advanced/metastatic kidney cancer fails to improve progression-free survival

The US Food and Drug Administration (FDA) has granted the drug CB-839 fast track development status when used in combination with cabozantinib for the treatment of patients with metastatic renal cell carcinoma (RCC) who received one or two prior courses of drug treatment (including at least one TKI). Fast track status speeds up the review […]

read more

FDA grants Fast Track designation to glutaminase inhibitor combination for metastatic kidney cancer

The glutaminase inhibitor, CB-839 has been granted Fast Track designation by the US Food and Drug Administration (FDA) in combination with cabozantinib (Cabometyx) for the treatment of people with metastatic renal cell carcinoma (mRCC) who have previously received one or two drug treatments. The FDA’s Fast Track programme speeds up the development, review and approval […]

read more

FDA grants fast track designation to glutaminase inhibitor CB-839 in combination with cabozantinib for metastatic kidney cancer

Calithera Biosciences announced earlier this week that the US Food and Drug Administration (FDA) has granted fast track designation to CB-839 for use in combination with cabozantinib for the treatment of patients with metastatic renal cell carcinoma (RCC) who received one or two prior courses of treatment (including at least one TKI). Fast track designation by the FDA […]

read more

New drug shows promise in combination with cabozantinib for the treatment of advanced kidney cancer

Results from a phase 1 clinical trial looking at CB-839, a first in class glutaminase inhibitor, in combination with cabozantinib, an oral tyrosine kinase inhibitor (TKI), for the treatment of advanced renal cell carcinoma (RCC) have been released. Preliminary results show the combination demonstrated a 40% overall response rate in advanced clear cell RCC patients, […]

read more

Initiation of phase 2 clinical trial of glutaminase inhibitor plus everolimus for renal cell carcinoma

Calithera Biosciences, an American pharmaceutical company focused on developing drugs for the treatment of cancer, has announced the initiation of a randomised phase 2 clinical trial of CB-839, a glutaminase inhibitor, combined with everolimus (Afinitor)‎ in patients with clear cell renal cell carcinoma (RCC). Many cancers are dependent on the nutrient glutamine for growth and […]

read more

FDA grants fast track designation to new glutaminase inhibitor CB-839 for metastatic kidney cancer

Calithera Biosciences announced yesterday that the FDA has granted fast track designation to CB-839 for use in combination with everolimus for the treatment of patients with metastatic renal cell carcinoma (RCC) who received at least two prior courses of treatment. Fast track designation by the FDA expedites the review process to facilitate development of drugs which treat […]

read more

New drug shows promise in kidney cancer in combination with everolimus

A new drug that targets a key enzyme that cancer cells need to keep them alive has been shown to be effective at controlling clear cell and papillary renal cell carcinoma (RCC) when given in combination with the mTOR inhibitor, everolimus. The results from a phase I clinical trial with the new drug, CB-839, were […]

read more
Showing all 8 results
  TOP